Left ventricular hypertrophy contributes to Myocardial Ischemia in Non-obstructive Coronary Artery Disease (the

Ingeborg Eskerud1, Eva Gerdts2, Terje H Larsen3

  • 1Department of Clinical Science, University of Bergen, PO box 7804, N-5020 Bergen, Norway.

Insights

Left ventricular hypertrophy (LVH) is linked to myocardial ischemia in patients with non-obstructive coronary artery disease (CAD). This finding suggests LVH may independently contribute to ischemia in this patient group.

Area of Science:

  • Cardiology
  • Cardiovascular Imaging
  • Medical Diagnostics

Background:

  • Mechanisms of myocardial ischemia in non-obstructive coronary artery disease (CAD) remain unclear.
  • Investigating the association between left ventricular hypertrophy (LVH) and myocardial ischemia in patients with stable angina and non-obstructive CAD.

Purpose of the Study:

  • To determine if left ventricular hypertrophy (LVH) is associated with myocardial ischemia in patients diagnosed with stable angina and non-obstructive coronary artery disease (CAD).

Main Methods:

  • 132 patients with stable angina and non-obstructive CAD (<50% stenosis via CCTA) underwent myocardial contrast stress echocardiography.
  • LVH was defined by LV mass index; myocardial ischemia was assessed by echocardiography.
  • Patients were categorized based on the presence and extent of ischemia.

Main Results:

  • Myocardial ischemia was detected in 52% of patients.
  • Patients with ischemia showed a higher prevalence of LVH (23% vs. 10%, p=0.035).
  • LVH independently correlated with the presence (OR 3.27, p=0.031) and extent (β=0.22, p=0.012) of myocardial ischemia.

Conclusions:

  • Left ventricular hypertrophy (LVH) is an independent predictor of myocardial ischemia in patients with stable angina and non-obstructive CAD.
  • LVH contributes to both the occurrence and severity of myocardial ischemia in this population.
  • These findings highlight LVH as a significant factor in non-obstructive CAD-related ischemia.
Abstract

Related Concept Videos

Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
958
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
409
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
238
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
622
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
358
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies01:27

Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies

Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
3.1K